Answers are grounded in this paper and cite their sources.
Reports outcomes of the DiaTAP bioCarbon button-graft in hemodialysis patients with difficult vascular access, indicating functional utility when traditional access options fail.
The outcome and complications which developed in 8 hemodialysis patients who received 12 DiaTAP bioCarbon button vascular-access devices were reviewed. All patients had a poor vascular access history. Three of twelve devices have been replaced because of thrombosis and two because of infection. Four patients have had 10 episodes of reduced blood flow. Streptokinase infusion into the DiaTAP button led to improved blood flow in 8 of 10 episodes. The 6-month survival rate of the DiaTAP access device was 67% and the average functioning life was 9.4 months. It was a valuable form of access when others had failed.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: